Cargando…

Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma

BACKGROUND: Sunitinib is a tyrosine kinase inhibitor with effective therapeutic outcomes in patients with renal-cell carcinoma. The study were to analyze the association of single-nucleotide polymorphisms present in cell-free DNA and pharmacokinetics with sunitinib treatment-emergent adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuanyuan, Mai, Haixing, Guo, Gang, Bi, Guofang, Hao, Guangtao, Li, Yuanyuan, Wang, Xiaofang, Cheng, Longmei, Wang, Jing, Dong, Ruihua, Liu, Zeyuan, Chen, Lijun, Qu, Hengyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865657/ https://www.ncbi.nlm.nih.gov/pubmed/29581831 http://dx.doi.org/10.18632/oncotarget.23881

Ejemplares similares

Development and validation of a HPLC-MS/MS method with electrospray ionization for quantitation of potassium oxonate in human plasma: Application to a pharmacokinetic study
por: HAO, GUANGTAO, et al.
Publicado: (2013)

In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study
por: Mai, Haixing, et al.
Publicado: (2017)

Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma
por: Domagała-Haduch, Małgorzata, et al.
Publicado: (2016)

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

Generative adversarial networks for detecting contamination events in water distribution systems using multi-parameter, multi-site water quality monitoring
por: Li, Zilin, et al.
Publicado: (2022)

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
por: Kloth, Jacqueline S. L., et al.
Publicado: (2015)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐dose study
por: Li, Lijun, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib
por: Noda, Satoshi, et al.
Publicado: (2012)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Pharmacokinetics and bioequivalence of sunitinib and Sutent(®) in Chinese healthy subjects: an open-label, randomized, crossover study
por: Wang, Yanli, et al.
Publicado: (2023)

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer
por: Dempsey, Jacqueline M., et al.
Publicado: (2018)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()
por: Chen, Yen-Yang, et al.
Publicado: (2014)

Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study
por: Koldenhof, J. J., et al.
Publicado: (2018)

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer
por: Diekstra, MH, et al.
Publicado: (2017)

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
por: Hansson, E K, et al.
Publicado: (2013)

Two Novel SNPs in RET Gene Are Associated with Cattle Body Measurement Traits
por: Gao, Yuan, et al.
Publicado: (2019)

Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
por: Assmus, Frauke, et al.
Publicado: (2022)

Blocking autocrine VEGF signaling by sunitinib, an anti-cancer drug, promotes embryonic stem cell self-renewal and somatic cell reprogramming
por: Chen, Guofang, et al.
Publicado: (2014)

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Genome-Wide SNPs and InDels Characteristics of Three Chinese Cattle Breeds
por: Zhang, Fengwei, et al.
Publicado: (2019)

Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea
por: Baek, Seon Ha, et al.
Publicado: (2014)

Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1
por: Cheng, Xuewei, et al.
Publicado: (2017)

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors
por: Wang, Erjian, et al.
Publicado: (2021)

Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Porta, C
Publicado: (2010)

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Charbonneau, C, et al.
Publicado: (2010)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2022)

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
por: Fujiwara, Yutaka, et al.
Publicado: (2016)

Association between the SNPs of the TOB1 gene and gastric cancer risk in the Chinese Han population of northeast China
por: Wang, Hui, et al.
Publicado: (2018)

Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma
por: Chen, Tingting, et al.
Publicado: (2022)

Three‐Component Mixture Model‐Based Adverse Drug Event Signal Detection for the Adverse Event Reporting System
por: Zhang, Pengyue, et al.
Publicado: (2018)

A Comprehensive Review of the Chemistry, Pharmacokinetics, Pharmacology, Clinical Applications, Adverse Events, and Quality Control of Indigo Naturalis
por: Sun, Quan, et al.
Publicado: (2021)

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder
por: Dong, Ruihua, et al.
Publicado: (2019)

Sunitinib Induced Immune Thrombocytopenia
por: Shekarriz, Ramin, et al.
Publicado: (2015)

Sunitinib: the antiangiogenic effects and beyond
por: Hao, Zhonglin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k5i8dnnue108grvl9td6us6ugc